Raymond C Harris Selected Research

Type 1 Diabetes Mellitus (Autoimmune Diabetes)

1/2018	Inhibition of Epidermal Growth Factor Receptor Activation Is Associated With Improved Diabetic Nephropathy and Insulin Resistance in Type 2 Diabetes.
5/2015	EGF receptor deletion in podocytes attenuates diabetic nephropathy.
6/2014	Epidermal growth factor receptor inhibition slows progression of diabetic nephropathy in association with a decrease in endoplasmic reticulum stress and an increase in autophagy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Raymond C Harris Research Topics

Disease

41	Fibrosis (Cirrhosis) 03/2024 - 04/2003
36	Diabetic Nephropathies (Diabetic Nephropathy) 10/2022 - 10/2006
22	Albuminuria 01/2021 - 01/2005
20	Acute Kidney Injury (Acute Renal Failure) 01/2024 - 02/2000
20	Hypertension (High Blood Pressure) 11/2018 - 03/2002
11	Chronic Renal Insufficiency 01/2024 - 03/2015
10	Inflammation (Inflammations) 11/2023 - 04/2002
9	Kidney Diseases (Kidney Disease) 01/2023 - 03/2014
9	Hyperglycemia 01/2020 - 12/2006
8	Ischemia 11/2023 - 02/2000
6	Renal Insufficiency (Renal Failure) 01/2023 - 10/2008
6	Neoplasms (Cancer) 02/2021 - 01/2004
5	Insulin Resistance 01/2022 - 10/2017
5	Reperfusion Injury 01/2018 - 07/2012
5	Ureteral Obstruction 01/2018 - 04/2010
4	Diabetes Mellitus 01/2021 - 03/2004
4	Carcinogenesis 01/2016 - 04/2009
4	Hypertrophy 06/2015 - 05/2005
3	Hypoxia (Hypoxemia) 10/2021 - 06/2014
3	Type 2 Diabetes Mellitus (MODY) 10/2021 - 01/2018
3	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2018 - 06/2014
3	Adenoma (Adenomas) 10/2015 - 04/2009
3	Essential Hypertension 04/2012 - 11/2009
3	Proteinuria 07/2011 - 09/2002
2	Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal) 03/2024 - 01/2022
2	Sarcoma (Soft Tissue Sarcoma) 03/2024 - 01/2020
2	Body Weight (Weight, Body) 01/2022 - 01/2021
2	Weight Gain 01/2022 - 03/2002
2	Obesity 01/2022 - 12/2018
2	Infections 01/2022 - 09/2004
2	Polyuria 05/2015 - 04/2005
2	Diabetes Complications 05/2015 - 01/2013
2	Wounds and Injuries (Trauma) 01/2013 - 10/2011

Drug/Important Bio-Agent (IBA)

19	ErbB Receptors (EGF Receptor)IBA 11/2023 - 01/2004
12	CollagenIBA 03/2024 - 08/2004
12	SaltsIBA 11/2018 - 09/2002
11	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 04/2023 - 01/2007
10	Dinoprostone (PGE2)FDA Link 04/2023 - 04/2009
10	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2004
8	ProstaglandinsIBA 04/2023 - 04/2005
8	Dopamine (Intropin)FDA LinkGeneric 03/2015 - 11/2009
7	CytokinesIBA 12/2022 - 12/2012
7	Angiotensin IIIBA 10/2021 - 06/2006
6	SodiumIBA 01/2023 - 03/2002
6	Heparin-binding EGF-like Growth Factor (HB-EGF)IBA 01/2017 - 04/2003
6	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 07/2011 - 09/2002
5	Messenger RNA (mRNA)IBA 10/2021 - 09/2002
5	Sirolimus (Rapamycin)FDA Link 07/2015 - 05/2005
5	Streptozocin (Streptozotocin)FDA Link 05/2015 - 09/2002
5	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 01/2014 - 10/2006
4	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2014
4	RNA (Ribonucleic Acid)IBA 10/2021 - 05/2005
4	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2021 - 03/2015
4	CreatinineIBA 12/2018 - 01/2007
4	Epidermal Growth Factor (EGF)IBA 01/2018 - 04/2003
4	Diphtheria ToxinIBA 12/2017 - 12/2012
4	TOR Serine-Threonine KinasesIBA 06/2014 - 05/2005
4	4- (5- (4- chlorophenyl)- 3- (trifluoromethyl)- 1H- pyrazol- 1- yl)benzenesulfonamideIBA 02/2007 - 09/2002
4	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 04/2005 - 04/2002
3	MafB Transcription FactorIBA 04/2023 - 01/2022
3	EnzymesIBA 01/2023 - 11/2009
3	C.I. direct red 80IBA 10/2022 - 12/2018
3	Losartan (Cozaar)FDA LinkGeneric 10/2021 - 11/2012
3	Biomarkers (Surrogate Marker)IBA 07/2021 - 01/2019
3	IntegrinsIBA 01/2020 - 05/2007
3	Phosphotransferases (Kinase)IBA 01/2019 - 01/2012
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 07/2012
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2018 - 05/2007
3	Tyrosine Kinase InhibitorsIBA 07/2016 - 06/2006
3	Superoxides (Superoxide)IBA 05/2015 - 06/2009
3	Dopamine Receptors (Dopamine Receptor)IBA 03/2015 - 01/2012
3	GlucocorticoidsIBA 09/2013 - 06/2005
3	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 04/2009 - 03/2002
3	Indicators and Reagents (Reagents)IBA 01/2008 - 03/2007
2	Epoprostenol (Prostacyclin)FDA LinkGeneric 12/2023 - 04/2009
2	PotassiumIBA 01/2023 - 12/2022
2	Interferon Regulatory FactorsIBA 01/2022 - 01/2021
2	aristolochic acid I (aristolochic acid)IBA 01/2022 - 09/2015
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 10/2021 - 02/2012
2	Vasopressins (Vasopressin)IBA 01/2021 - 04/2005
2	AdiponectinIBA 01/2021 - 01/2018
2	Blood Glucose (Blood Sugar)IBA 01/2018 - 10/2008
2	setogepramIBA 01/2018 - 01/2018
2	AlbuminsIBA 01/2018 - 12/2006
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2018 - 03/2014
2	Insulin (Novolin)FDA Link 01/2018 - 12/2006
2	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2018 - 09/2015
2	Caspase 3 (Caspase-3)IBA 10/2016 - 09/2014
2	Aquaporins (Water Channels)IBA 03/2016 - 10/2008
2	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2016 - 07/2015
2	Glycogen Synthase (Synthase I)IBA 08/2015 - 11/2012
2	Mechanistic Target of Rapamycin Complex 1IBA 07/2015 - 06/2015
2	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2013 - 11/2012
2	Superoxide DismutaseIBA 12/2012 - 06/2009
2	Captopril (Capoten)FDA LinkGeneric 11/2012 - 02/2012
2	Acetates (Acetic Acid Esters)FDA Link 11/2012 - 11/2009
2	Desoxycorticosterone (Deoxycorticosterone)IBA 11/2012 - 11/2009

Therapy/Procedure

11	Therapeutics 01/2022 - 09/2004
7	Nephrectomy 11/2023 - 09/2002
3	Chemoprevention 10/2015 - 04/2009